Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cobiprostone - Sucampo Pharmaceuticals

Drug Profile

Cobiprostone - Sucampo Pharmaceuticals

Alternative Names: RU-8811; SPI-8811

Latest Information Update: 06 Mar 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sucampo Pharmaceuticals
  • Class Fatty acids; Small molecules
  • Mechanism of Action Chloride channel agonists; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Gastro-oesophageal reflux; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; NSAID-induced ulcer; Portal hypertension; Stomatitis; Wounds

Most Recent Events

  • 13 Feb 2018 Sucampo Pharmaceuticals has been acquired by Mallinckrodt
  • 11 Jul 2016 Discontinued - Phase-I for Stomatitis (In volunteers) in Japan (PO)
  • 11 Jul 2016 Discontinued - Phase-II for NSAID-induced ulcer (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top